Gilvetmab is a caninized anti-PD-1 monoclonal antibody that has obtained conditional approval for veterinary use in dogs. Gilvetmab is under active research for stage I, II, or III mast cell tumors and stage II or III melanoma. it is an competitive immune checkpoint inhibitor,attracting interests in the cancer research field.
Reinheit:
95.00%
CAS Nummer:
[1808081-43-7]
Target-Kategorie:
PD-1/PD-L1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten